Below are frequently asked questions about the Otsuka Patient Assistance Foundation, Inc. (OPAF). If you don’t see your question answered below, please call 1-855-727-6274 for further information.
The Otsuka Patient Assistance Foundation, Inc. (OPAF) is an organization that provides free treatment to eligible uninsured and underinsured patients on ABILIFY® (aripiprazole) Tablets, ABILIFY MAINTENA® (aripiprazole), JYNARQUE® (tolvaptan), REXULTI® (brexpiprazole), or SAMSCA® (tolvaptan) medications.
Eligible patients prescribed ABILIFY MAINTENA or JYNARQUE can receive nursing support to help with managing shipments and refills of these medications.
Eligible patients prescribed JYNARQUE can also receive reimbursement up to $500.00 annually for REMS-required laboratory tests. Reimbursement assistance is also available to help with out-of-pocket expenses for lab services.
Patients and healthcare providers can call 1-855-727-6274 to reach the Otsuka Patient Assistance Foundation, Inc. (OPAF).
Yes. Patients must have a diagnosis that is within the drug's approved indication(s) to qualify for no cost medications from the Otsuka Patient Assistance Foundation, Inc. (OPAF) This means patients who are being treated with Otsuka medications for conditions not indicated in the medication's approved Prescribing Information will not qualify for free treatment. Please contact a Dedicated Patient Case Coordinator by dialing 1-855-727-6274 if further clarification is needed.
Medication will be sent to a patient’s home or their clinician’s office. The location is determined by the medication selection in the application.
The Otsuka Patient Assistance Foundation, Inc. (OPAF) is funded by donations.
Currently the Otsuka Patient Assistance Foundation, Inc. (OPAF) only provides free medication to eligible patients.
Patients receiving government issued insurance (Medicare, Medicare Part D, Medicaid) need to reapply at the end of every calendar year. Other qualified patients not on a government issued insurance program must reapply every 12 months.